Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery

NCT ID: NCT04228692

Last Updated: 2023-07-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-03-11
• Study Completion Date: 2022-06-11

Brief Summary

Symptomatic endometriosis can be responsible for urinary problems as well as symptoms of clinical bladder hyperactivity and/or symptoms of bladder pain before or during miction that can persist after bladder voiding. Whereas urinary problems can predate surgery due to the endometrial lesions themselves, the surgery can also have functional consequences for urinary function, specifically when there is trauma (incisions, per-operative coagulation) to the inferior hypogastric nerve fibers and/or to the hypogastric plexus.

The incidence of post-surgery urinary symptoms could be as high as 30%. The incidence of voiding problems and specifically of non-obstructive voiding dysfunction can be observed in 17,5% of cases of patients 1-month post-surgery for deep colorectal endometriosis, and persists in 4,8% of women after 12 months.

The gold standard for treatment of voiding problems consists of self-catheterization, as is the case for all non-obstructive voiding dysfunction symptoms. This procedure considerably impacts quality of life. The proper and complete voiding of the bladder remains essential in order to avoid recurring urinary tract infections and pelvic static disorder.

In the case of persistent dysuria, the use of self-catheterization is necessary in 21% of patients after surgery for deep endometriosis, for an average duration of 85 days. To date, few studies have explored the management of post-operative urinary complications after surgery for deep endometriosis. Pharmaceutical alternatives (alpha-blockers, anticholinergics, benzodiazepines) have not proven effective and sometimes cause side effects. However promising alternative treatments are being developed, specifically the neuromodulation of the sacral root. This procedure has been shown effective in the treatment of non-obstructive voiding dysfunction; however, it remains an invasive treatment that has its load of complications and undesirable side-effects. A recent study reports favorable results for the use of sacral neuromodulation in the case of persistent incomplete voiding following surgery for deep colorectal endometriosis. Some studies have also suggested that percutaneous posterior tibial nerve stimulation (PTN) could also be a treatment alternative. The advantage of this procedure is that it is non-invasive and less constraining. No study has yet evaluated whether PTN could also be used to treat patients with persistent voiding dysfunction following surgery for deep endometriosis.

Our study, conducted in the gynecologic department of Croix ROUSSE Hospital, Lyon (France), evaluates PTN as a new treatment option for post-operative voiding dysfunction in women who suffer from deep endometriosis. Our aim is to prove that the use of PTN can reduce the duration of self-catheterization by 50% when compared to self-catheterization only.

Conditions

Endometriosis; Dysuria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Self-catheterization only

Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary

Group Type: ACTIVE_COMPARATOR

Self-catheterization only

Intervention Type: PROCEDURE

Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.

Posterior tibial nerve stimulation + self-catheterization

Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization.

Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.

Group Type: EXPERIMENTAL

Posterior tibial nerve stimulation + self-catheterization

Intervention Type: DEVICE

Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.

Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.

Interventions

Self-catheterization only

Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.

Intervention Type: PROCEDURE

Posterior tibial nerve stimulation + self-catheterization

Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.

Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patients who are eligible for the French public healthcare system
• Patients who have given their consent for this research

Exclusion Criteria

• Patients with cognitive, psychiatric or motor disturbances, that do not allow for independent use of the device
• Patients who do not speak French
• Patients who have had a surgery (bladder or ureters) for endometriosis or any other reason.
• Patients who were participating in another ongoing study, or within the exclusion time stipulated by another study (at the discretion of the investigator)
• Patients unable to give their consent (protected by law: under guardianship / trusteeship)
• Patients who are taking a pharmaceutical treatment for urological problem (anticholinergics, alpha-blockers, prostaglandin)
• Pregnant or breastfeeding women
• Patients with a pacemaker
• Patients with dermatological problem in the area where the device's electrodes have to be installed

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sophie WAREMBOURG, Dr

Role: PRINCIPAL_INVESTIGATOR

Hospices Civils de Lyon

Locations

Hôpital de la Croix Rousse

Lyon, , France

Countries

France

Other Identifiers

2019-A02583-54

Identifier Type: OTHER

Identifier Source: secondary_id

69HCL19_0686

Identifier Type: -

Identifier Source: org_study_id